Home › Free Stock Grades › CCCC
C4 Therapeutics, Inc. (CCCC) Stock Grade
CCCC · Healthcare
B+
Market Cap
$158.3M
P/E Ratio
—
Revenue Growth (YoY)
+1.0%
Net Margin
-292.1%
Return on Equity
—
Dividend Yield
None
About C4 Therapeutics, Inc.'s fundamentals
C4 Therapeutics is a small-cap biotechnology company with a market capitalization of $158.3 million that reported minimal revenue growth of 1.0% year-over-year in its latest period. The company operates at a significant loss, with a net margin of -292.1%, meaning its expenses substantially exceed its revenues. The company does not pay a dividend and reported a net loss in its most recent annual statement, which is typical for early-stage biotech firms investing heavily in research and development.